



JOINT TRANSNATIONAL CALL 2016:

"Minimally and non-invasive methods for early detection and/or progression of cancer"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to

If you have any questions about this form, please do not hesitate to contact us at

Note: Fields marked with a * are mandatory

Contact Information	
First name *	Daniela
Last name *	Saggioro
Position *	Senior Researcher
Telephone number	+ 39 049 8215884/5835
E-mail address*	daniela.saggioro@ioveneto.it
Website address	http://ioveneto.it/
Institution/Organisation *	Veneto Institute of Oncology IOV-IRCCS
Department*	Immunology and Molecular Oncology
Street	Via Gattamelata 64
Postal Code / City *	35128
Country *	Italy

***I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

YES



SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal

Project title (draft):

Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):



OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

The main area of interest of our lab. regards the detection of both diagnostic biomarkers and markers of progression in cancer. Today, cfDNA is becoming an important tool for noninvasive diagnosis and the monitoring of tumor dynamics. However, the detection and clinical use of cfDNA in oncology still remain a challenge due to the mixture of tumor and normal cfDNA. To date, new technological advances, such as droplet digital PCR (ddPCR) and next generation sequencing (NGS) have enabled the detection of circulating tumor free DNA, paving the way for its clinical use.

We have a high level of knowledge of tumor genetics and, more recently, we have developed expertise on cfDNA detection and analysis. We are using the mini-invasive liquid biopsy approach to monitor the risk of neoplastic progression in Barrett's esophagus patients, and to follow tumor behavior in esophageal adenocarcinoma patients. However, we are also very interested in the application of our expertise on cfDNA in other tumor entities.

All facilities and skills required for the standard molecular biology techniques are part of our laboratory. Moreover, our Institution has the most innovative instrumentation necessary to perform new emerging molecular techniques such as NGS (Illumina MiseqDX platform), CTCs isolation (CELLSEARCH® Circulating Tumor Cell), ddPCR (QX200 ddPCR™). Our Institution has numerous contacts with major Laboratories in Italy and Europe, and we are looking for creating partnership with other countries.

Recent publications:

- Boldrin E, Rumiato E, Fassan M, Balsamo L, Realdon S, Battaglia G, Rugge M, Amadori A, Saggiaro D. Liquid biopsy as a novel predictive tool in Barrett's esophagus carcinogenesis: two representative cases. *Transl Res.* 2016 Oct;176:127-31. doi:10.1016/j.trsl.2016.05.001.
- Rumiato E, Boldrin E, Malacrida S, Battaglia G, Bocus P, Castoro C, Cagol M, Chiarion-Sileni V, Ruol A, Amadori A, Saggiaro D. A germline predictive signature of response to platinum chemotherapy in esophageal cancer. *Transl Res.* 2016 May;171:29-37.e1. doi: 10.1016/j.trsl.2015.12.011. Epub 2015 Dec 22.
- Rumiato E, Brunello A, Ahcene-Djaballah S, Borgato L, Gusella M, Menon D, Pasini F, Amadori A, Saggiaro D, Zagonel V. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetics study. *Pharmacogenomics J.* 2015 Oct 27. doi: 10.1038/tpj.2015.73. [Epub ahead of print]
- Boldrin E, Rumiato E, Fassan M, Rugge M, Cagol M, Marino D, Chiarion-Sileni V, Ruol A, Gusella M, Pasini F, Amadori A, Saggiaro D. Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. *The Pharmacogenomics Journal*, 9 June 2015. doi:10.1038/tpj.2015.41. Epub 2015 Jun 9.
- Boldrin E, Rumiato E, Fassan M, Cappellesso R, Rugge M, Chiarion-Sileni V, Ruol A, Alfieri R, Cagol M, Castoro C, Amadori A, Saggiaro D. Genetic features of metachronous esophageal cancer developed in Hodgkin's lymphoma or breast cancer long-term survivors: an exploratory study. *PLoS One.* 2015 Jan 22;10(1):e0117070. doi: 10.1371/journal.pone.0117070. eCollection 2015.
- Rumiato E, Cavallin F, Boldrin E, Cagol M, Alfieri R, Basso D, Castoro C, Ancona E, Amadori A, Ruol A, Saggiaro D. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in



esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Pharmacogenetics and Genomics. 2013 Nov;23(11):597-604. doi: 10.1097/FPC.0b013e3283653afc.